Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Novavax has been awarded a contract valued at up to $179 million by the Biomedical Advanced Research & Development Authority (BARDA) for development of recombinant vaccines for the prevention of seasonal and pandemic influenza. During the contract’s three-year base period, valued at $97 million, the company will develop and manufacture its clinical-stage virus-like-particle vaccines. The contract could be extended an additional two years with $82 million in funding. BARDA, part of the Department of Health & Human Services, has awarded a similar flu vaccine contract to VaxInnate. It is valued at up to $196 million, including a $118 million three-year base period and an option to extend for two years.
This article has been sent to the following recipient: